NEW YORK – Spatial omics informatics company Nucleai said Monday that it has entered a strategic collaboration with digital pathology and molecular diagnostics firm GoPath Diagnostics.
Under the collaboration, the companies aim to combine Nucleai's spatial biology and AI technologies with GoPath's data collections and laboratory capabilities to develop digital pathology tools for clinical trials and diagnostics.
Financial and other terms of the agreement were not disclosed.
Nucleai will integrate its AI algorithms and digital pathology viewer with GoPath's laboratory information management systems (LIMS) and laboratory management systems (LMS) to enable real-time sharing of data and centralized AI analysis to aid clinicians' review of diagnostic pathology cases.
The companies will also collaborate on research projects aimed at developing predictive AI algorithms that could provide insights into indications in cancer and immunology, including prostate cancer and inflammatory bowel disease.
Additionally, they intend to use their combined capabilities for clinical trial work, providing centralized access to real-world training and validation datasets, molecular and pathology services, and AI tools.
The solutions developed through the collaboration will be deployed in an environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
"The use of AI spatial biomarkers to make treatment decisions is inevitable, and it's not a question of if but when," Nucleai CEO Avi Veidman said in a statement. "As pioneers in this field, Nucleai is making sure that AI spatial biomarkers are actionable sooner than people think. The partnership with GoPath is a critical step in realizing this vision by complementing our AI spatial capabilities with their digital pathology expertise so we can deploy AI spatial biomarkers into clinical and diagnostic use for broader adoption."
"Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow," Jim Lu, CEO and medical director for GoPath, said in a statement. "This workflow is fully digital, spanning from initial digitization to an intuitive viewing platform, powered by advanced AI algorithms for efficient case management and sign-out processes. By incorporating Nucleai's innovative AI technology, we're significantly enhancing diagnostic accuracy and the efficacy of treatment strategies within the healthcare sector."
The announcement follows news last week that Nucleai closed a $14 million funding round.